Research Intelligence & Discovery - software & AI news

Daily news on software, AI, and companies shaping research intelligence & discovery.

Showing 51 results
A minimalist representation of AI technology in biopharma.

May 20, 2026

Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for the Global Biopharma and Healthcare

Cohere has expanded its capabilities in the biopharma and healthcare sectors by acquiring Reliant AI, a company specializing in AI solutions for these industries. This strategic move aims to enhance Cohere's sovereign AI offerings, ensuring compliance with security and regulatory standards crucial for healthcare applications.The acquisition integrates Reliant AI's advanced technology and proprietary biomedical datasets into Cohere's existing platforms, thereby strengthening its presence in Canad
Molecular structure symbolizing AI in biotech

May 16, 2026

Sen. David McCormick tours AI-powered biotech labs at Penn to promote AI and federal funding admit NSF turmoil

Senator David McCormick recently visited an AI-driven biotech lab at the University of Pennsylvania to emphasize the transformative role of artificial intelligence in biomedical research and drug development.During his tour of AIRFoundry, a National Science Foundation-funded facility, McCormick expressed admiration for the innovative strides being made in the field. Researchers at the lab highlighted how AI is revolutionizing biomedical research by enabling the rapid analysis of large datasets,
A computer model of a molecular structure in a research lab

Apr 24, 2026

Boehringer Ingelheim Launches AI and Machine Learning Centre in London

Boehringer Ingelheim has inaugurated a new AI and machine learning centre in London, reflecting a significant investment in enhancing drug discovery and patient care.Situated in King’s Cross, this facility is part of a £150 million ($202.7 million) investment over the next decade, aimed at embedding AI technologies into the company's research and development processes. The centre's primary focus will be on creating computational models that deepen the understanding of disease biology, ultimately